Identification of nuclear factor-κB inhibitors in the folk herb Rhizoma Menispermi via bioactivity-based ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry analysis

BMC Complementary and Alternative Medicine

Gang Bai¹  Yuanyuan Hou¹  Yan Nie¹  Yanqi Han¹  Binfeng Cheng¹  Xuhui Ying¹  Mengge Zhou¹  Dan Sun¹ 

[1] State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300071, China

关键词: Anti-inflammation;    Rhizoma Menispermi;    UPLC/Q-TOF MS;    NF-κB inhibitor;    Bioactive constituent identification;   

Others  :  1086555
DOI  :  10.1186/1472-6882-14-356

 received in 2014-07-11, accepted in 2014-09-19,  发布年份 2014

【 摘 要 】

Background

Rhizoma Menispermi (RM) is the dried root of Menispermum dauricum DC, which is traditionally used to treat swelling and pain for sore throat, enteritis and rheumatic arthralgia in the clinic, but its bioactive compounds remain unclear.

Methods

In this study, RM extract was administered orally to ICR mice followed by challenging with an intratracheal Pseudomonas aeruginosa suspension. Then mortality, histological features of lung, and inflammatory cytokines were evaluated. RM treatment significantly ameliorated Pseudomonas aeruginosa-induced acute lung inflammation and reduced levels of inflammatory mediators. To screen for potential anti-inflammatory constituents of the RM extract, a simple and rapid method based on ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-Q/TOF MS) coupled with a luciferase reporter assay system to detect nuclear factor-κB (NF-κB) activity was established.

Results

Using this system, seven potential NF-κB inhibitors were detected, including sinomenine, norsinoacutin, N-norsinoacutin-β-D-glucopyranoside, 6-O-methyl-laudanosoline-13-O-glucopyranoside, magnoflorine, laurifloline and dauricinoline. Furthermore, IL-6 and IL-8 assays confirmed the anti-inflammatory effects of these potential NF-κB inhibitors, in which norsinoacutin, 6-O-methyl-laudanosoline-13-O-glucopyranoside laurifloline, dauricinoline and N-norsinoacutin-β-D-glucopyranoside were revealed as new NF-κB inhibitors.

Conclusion

This method of UPLC-Q/TOF coupled with the luciferase reporter assay system was initially applied to the study of RM and was demonstrated to represent a simple, rapid and practical approach to screen for anti-inflammatory compounds. This study provided useful results for further investigation on the anti-inflammatory mechanism of RM.

【 授权许可】

   
2014 Sun et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Hai CM: Airway smooth muscle cell as therapeutic target of inflammation. Curr Med Chem 2007, 14(1):67-76.
• [2]Matthay MA, Zimmerman GA: Acute lung injury and the acute respiratory distress syndrome - four decades of inquiry into pathogenesis and rational management. Am J Resp Cell Mol 2005, 33(4):319-327.
• [3]Bismarck PV, Winoto MS, Herzberg M, Uhlig U, Schuetze S, Lucius R, Krause MF: IKK NBD peptide inhibits LPS induced pulmonary inflammation and alters sphingolipid metabolism in a murine model. Pul Pharmacol & Ther 2012, 25(3):228-235.
• [4]Li QT, Verma IM: NF-kappa B regulation in the immune system. Nat Rev Immunol 2002, 2(10):725-734.
• [5]Hoesel B, Schmid JA: The complexity of NF-kappa B signaling in inflammation and cancer. Mol Cancer 2013, 12:86-101. BioMed Central Full Text
• [6]Baldwin AS: Series introduction: the transcription factor NF-kappa B and human disease. J Clin Invest 2001, 107(1):3-6.
• [7]Sun Z, Andersson R: NF-κB activation and inhibition: a review. Shock 2002, 18(2):99-106.
• [8]Petrova RD, Reznick AZ, Wasser SP, Denchev CM, Nevo E, Mahajna J: Fungal metabolites modulating NF-kappa B activity: an approach to cancer therapy and chemoprevention (Review). Oncol Rep 2008, 19(2):299-308.
• [9]Wang Q, Kuang H, Su Y, Sun Y, Feng J, Guo R, Chan K: Naturally derived anti-inflammatory compounds from Chinese medicinal plants. J Ethnopharmacol 2013, 146(1):9-39.
• [10]Drayton DL, Liao S, Mounzer RH, Ruddle NH: Lymphoid organ development: from ontogeny to neogenesis. Nat Immunol 2006, 7(4):344-353.
• [11]Spco C: Pharmacopoeia of the people’s Republic of China. Beijing: Chinese medical science and technology press; 2010.
• [12]Bao GH, Qin GW, Wang R, Tang XC: Morphinane alkaloids with cell protective effects from Sinomenium acutum. J Nat Prod 2005, 68(7):1128-1130.
• [13]Jin HZ, Wang XL, Wang HB, Wang YB, Lin LP, Ding J, Qin GW: Morphinane alkaloid dimers from Sinomenium acutum. J Nat Prod 2008, 71(1):127-129.
• [14]Min YD, Choi SU, Lee KR: Aporphine alkaloids and their reversal activity of multidrug resistance (MDR) from the stems and rhizomes of Sinomenium acutum. Arch Pharm Res 2006, 29(8):627-632.
• [15]Sugimoto Y, Matsui M, Takikawa H, Sasaki M, Kato M: Dechlorodauricumine from cultured roots of Menispermum dauricum. Phytochemistry 2005, 66(22):2627-2631.
• [16]Zheng LN, Luo D, Sun R: The margin of safety study on anti-inflammatory effect of different components from Rhizoma Menispermi. Chin J Pharmacovigilance 2012, 9(6):335-337.
• [17]Liu X, Han F: Anti-inflammatory effect and acute toxicity of Menispermum Dauricum. Heilongjiang Med J 2000, 13(2):98-99.
• [18]Hou YY, Cao XL, Dong LY, Wang LQ, Cheng BF, Shi Q, Luo XD, Bai G: Bioactivity-based liquid chromatography-coupled electrospray ionization tandem ion trap/time of flight mass spectrometry for β2AR agonist identification in alkaloidal extract of Alstonia scholaris. J Chromatogr A 2012, 1227:203-209.
• [19]Li L, Luo GA, Liang QL, Hu P, Wang YM: Rapid qualitative and quantitative analyses of Asian ginseng in adulterated American ginseng preparations by UPLC/Q-TOF-MS. J Pharmaceut Biomed 2010, 52(1):66-72.
• [20]Cheng BF, Hou YY, Wang LQ, Dong LY, Peng JM, Bai G: Dual-bioactivity-based liquid chromatography-coupled quadrupole time-of-flight mass spectrometry for NF-κB inhibitors and β2AR agonists identification in Chinese Medicinal Preparation Qingfei Xiaoyan Wan. Anal Bioanall Chem 2012, 404(8):2445-2452.
• [21]Bai F, Xu HJ, Zhang Q, Qi XZ, Mou R, Bai G, Qiao MQ: Functional characterization of pfm in protein secretion and lung infection of Pseudomonas aeruginosa. Canadian J Microbiol 2011, 57(10):829-837.
• [22]Mulcahy LR, Isabella VM, Lewi K: Pseudomonas aeruginosa biofilm Potential therapeutic targets. Microb Ecol 2014, 68:1-12.
• [23]Fazli M, Almblad H, Rybtke ML, Givskov M, Eberl L, Tolker NT: Regulation of biofilm formation in Pseudomonas and Burkholderiaspecies. Environ Microbiol 2014, 16(7):1961-1981.
• [24]Sharma G, Rao S, Bansal A, Dang S, Gupta S, Gabrani R: Pseudomonas aeruginosa biofilm: potential therapeutic targets. Biologicals 2014, 42(1):1-7.
• [25]Sun HY, Fujitani S, Quintiliani R, Yu VL: Pneumonia due to pseudomonas aeruginosa part ii: antimicrobial resistance, pharmacodynamic concepts, and antibiotic therapy. Chest 2011, 139(5):1172-1185.
• [26]Talbot GH, Bradley J, Edwards JE, Gilbert D, Scheld M, Bartlett JG: Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006, 42(5):657-668.
• [27]Barnes PJ: Pathophysiology of allergic inflammation. Immunol Rev 2011, 242:31-50.
• [28]VanReeth K: Cytokines in the pathogenesis of influenza. Vet Microbiol 2000, 74(1–2):109-116.
• [29]Shan ZY, Xu HJ, Shi XQ, Yu Y, Yao HM, Zhang XM, Bai YL, Gao GC, Saris PEJ, Qiao MQ: Identification of two new genes involved in twitching motility in Pseudomonas aeruginosa. Microbiol-SGM 2004, 150:2653-2661.
• [30]Zhou J, Xie G, Yan X: Chemical component of source plants in tranditional Chinese medicine. Beijing: Science Press; 2009.
• [31]Yi L, Liang ZT, Peng Y, Yao X, Chen HB, Zhao ZZ: Tissue-specific metabolite profiling of alkaloids in Sinomenii Caulis using laser microdissection and liquid chromatography–quadrupole/time of flight-mass spectrometry. J Chromatogr A 2012, 1248:93-103.
• [32]Ciarcia R, Vitiello MT, Galdiero M, Pacilio C, Iovane V, D’Angelo D, Pagnini D, Caparrotti G, Conti D, Tomei V: Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients. J Cell Physiol 2012, 227(6):2798-2803.
• [33]Sharma U, Bala M, Kumar N, Singh B, Munshi RK, Bhalerao S: Immunomodulatory active compounds from Tinospora cordifolia. J Ethnopharmacol 2012, 141(3):918-926.
• [34]Xu M, Liu L, Qi C, Deng B, Cai X: Sinomenine versus NSAIDs for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Planta Med 2008, 74(12):1423-1429.
• [35]Li XJ, Yue PYK, Ha WY, Wong DYL, Tin MMY, Wang PX, Wong RNS, Liu L: Effect of sinomenine on gene expression of the IL-1β-activated human synovial sarcoma. Life Sci 2006, 79(7):665-673.
• [36]Kim BR, Seo HS, Ku JM, Kim GJ, Jeon C, Park J, Jang BH, Park SJ, Shin YC, Ko SG: Silibinin inhibits the production of pro-inflammatory cytokines through inhibition of NF-κB signaling pathway in HMC-1 human mast cells. Inflamm Res 2013, 62(11):941-950.
• [37]Blackwell TS, Blackwell TR, Christman JW: Induction of endotoxin tolerance depletes nuclear factor-kappaB and suppresses its activation in rat alveolar macrophages. J Leukocyte Biol 1997, 62(6):885-891.
• [38]Baeuerle PA, Baltimore D: NF-κB: ten years after. Cell 1996, 87(1):13-20.
• [39]Mercurio F, Manning AM: Multiple signals converging on NF-κB. Curr Opin Cell Biol 1999, 11(2):226-232.